Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three and nine months ended January 31, 2008 and an update on its programs.

Jim DeMesa, M.D., President & CEO of MIGENIX stated, "With the conclusion of our third fiscal quarter and now being halfway through our fourth quarter, we are looking forward to the completion of enrollment in the Phase III Omigard registration trial for preventing catheter-related infections being conducted by our partner, Cadence Pharmaceuticals. With completion of this trial, we expect to enter into a very important time of clinical results over the next half of the year (with both Omigard and celgosivir, our Phase II hepatitis C drug candidate) followed by our potential entry into the regulatory approval process in 2009 with Omigard."

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009. Under the terms of the agreement with Cadence, MIGENIX will receive up to US$27 million in development and commercialization milestone payments, upon the achievement of specified milestones, starting with the US and European regulatory submission process; and a double-digit royalty on net sales. MIGENIX has been and continues to be in discussions with p
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Feb. 13 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... 2008. The net loss for the second quarter of fiscal ... net loss of $5.9 million,or $0.23 per share, in the ... Total operating expenses were $4.9 million in the second quarter ...
... China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC ... manufacturer and distributor of high-quality, pharmaceutical grade,glucose products ... second,quarter of fiscal 2009 ended December 31, 2008. ... glucose products increased during the second quarter,compared with ...
... Creation Best Practice Findings to be released at SiriusDecisions B-to-B ... ... February 13, 2009 -- SiriusDecisions, the world,s leading source for ... announced that top executives from Hewlett-Packard Company, IBM Corporation and ...
Cached Biology Technology:Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 2Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 3Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 4Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 5Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 6Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 8Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 9Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 10Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 11Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 2Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 3
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... of Warwick are examining a way of using bacteria ... that are difficult to create synthetically on a lab ... called prodiginines. , This group of antibiotics has ... to target and kill cancer cells. A synthetic prodiginine ...
... newly created by the University of California, Berkeley, and Lawrence ... the body's cells that can be flipped on and off ... Optical switches like these could trigger a chemical reaction, initiate ... cell - all at the flash of a light. ...
... engineers have developed a computer tool they say could ... women to use to prevent infection by the virus ... is a pressing challenge because women now account for ... said. , By applying fundamentals of physics and chemistry, ...
Cached Biology News:Light-sensitive photoswitches could restore sight to those with macular degeneration 2Light-sensitive photoswitches could restore sight to those with macular degeneration 3Study defines effective microbicide design for HIV/AIDS prevention 2Study defines effective microbicide design for HIV/AIDS prevention 3
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... Tecans open platform for clinical diagnostic applications, ... performance in the clinical diagnostic and blood ... barcode reading and sample traceability as standard ... complies with the IVD-Directive* established in the ...
... Stabilizer is an aqueous solution that contains ... stabilizing chemicals in a MOPS buffer (3-(N-Morpholino) ... This product contains a combination of 0.02% ... 300 (Rohm and Haas Company) as a ...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
Biology Products: